PeptideWellness
Take the quiz
§ By goal
§ Most read
Featured · field guide
The 2026 GLP-1 telehealth field guide.

Where the category stands in May 2026 — what's available, who to trust, what costs what. 22-min read, medically reviewed.

Read the guide
§ The providers
Who sells what — and who to trust.

An independent overview of the compounded-GLP-1 telehealth market and the providers we cover — market size, what the FDA changed, and an honest read on each.

View the provider overviewAll 17 reviews
§ Learn
The educational layer, in progress.

Primers for newcomers and deep dives for the curious. The foundation articles are published; more are in the pipeline.

View all Learn articles
§ Interactive tools
60-second quiz PeptideMatch Start here Answer four questions, get a goal-matched protocol and provider. The record GLP-1 price history Every price change we have recorded, with the figure before and after it. Overview All tools The full tools page — quiz, the Index, its history, and how we build them. Method How we measure a price What counts as the price, where we read it, and how often it is re-checked.
Free to use Medically reviewed methodology How we build our tools
PeptideWellness Index
The GLP-1 Price Index

What compounded and branded semaglutide and tirzepatide actually cost, from each provider's own published pricing.

See the full index
503A · Coral Springs, FL

Cre8 Pharmacy

Contact pharmacy ↗

A Florida 503A compounder advertising peptide therapy and weight-loss formulas — PCAB-accredited for sterile and non-sterile compounding, with a practitioner-gated catalog.

Visit website ↗All compounders
Editorial independence

This profile is editorial. PeptideWellness has no commercial relationship with this pharmacy; coverage and assessment are never for sale.

Cre8 Pharmacy (legal name CRE8 Pharmacy Group, LLC) is a patient-specific 503A compounding pharmacy in Coral Springs, FL. It markets to prescribers, and its actual product catalog sits behind a practitioner login — so some specifics can’t be verified from the public site.

Facility & accreditation

Cre8 describes itself as a 503A compounding facility; it does not appear on the FDA Registered Outsourcing Facilities (503B) list [1], consistent with 503A-only, state-regulated operation. Its site has a dedicated page on its PCAB accreditation [2], and ACHC’s own directory confirms it [3]: PCAB accreditation for sterile compounding (USP 797), non-sterile compounding (USP 795) and hazardous drug handling (USP 800), from 20 December 2025 to 19 December 2028.

What they compound

The public site advertises “Peptide Therapy” and “Weight Loss Formulas” as categories, but the specific molecules (e.g., which peptides, semaglutide/tirzepatide) are behind a practitioner login and are not publicly listed [2]. So the peptide/GLP-1 focus is clear at the category level; the exact menu is practitioner-gated.

Regulatory record

We found no FDA warning letter for Cre8 in public sources. As a 503A pharmacy it isn’t on the FDA 503B inspection list [1]; primary oversight is Florida’s board of pharmacy. Absence from federal databases is not an exhaustive clean record.

The read

An on-audience 503A peptide/weight-loss compounder. Its PCAB accreditation checks out in ACHC’s registry. The caveat is the molecule catalog: it is practitioner-gated, so we can’t independently verify exactly what they compound. (Note: a claim circulating that Cre8 supplies the telehealth brand Hims is not supported by any source we found.)

References

  1. FDA — Registered Outsourcing Facilities (503B) list (Cre8 not listed → confirms 503A). (accessed 2026-07-04)
  2. Cre8 Pharmacy — official site. (accessed 2026-07-04)
  3. ACHC / PCAB accredited-organization directory (searched “Cre8”: Cre8 Pharmacy Group, LLC, PCAB Compounding Pharmacy, 12/20/2025 through 12/19/2028). (accessed 2026-10-27)

Other pharmacies in the directory

Contact pharmacy ↗
Contact pharmacy ↗